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We report a case of accidental subcutaneous infusion of remifentanil as a cause of delayed awakening after a craniotomy.
1.CaseReport
A 60-year-old male (5 5  , 73.7kg) presented for resection of
a left acoustic neuroma via a left retromastoid suboccipital
craniotomy. His past medical history was signiﬁcant only for
hypertension, which was well controlled with beta-blockade.
His physical examination and laboratory workup did not
reveal any abnormalities other than decreased hearing and
the presence of an acoustic neuroma on imaging studies. He
arrived in the operating room with a 20-gauge intravenous
catheter in the left hand at heplock. A second 18-gauge pe-
ripheral intravenous catheter (IV) was placed in the patient’s
right hand. After standard monitoring was applied according
torecommendationsoftheAmericanSocietyofAnesthesiol-
ogists,Midazolam2milligrams(mg)wasadministered.Gen-
eral anesthesia was induced with Thiopental 375mg, Fen-
tanyl 150micrograms (mcg), Lidocaine 60mg, and cis-atra-
curium 10mg. All intravenous medications for induction
were administered via the 18g intravenous catheter. Anes-
thesia was maintained with 0.5MAC Desﬂurane in Oxygen/
Nitrous Oxide 1/1.5liters per minutes and Remifentanil
(“Ultiva,” Abbott Laboratories, North Chicago, IL 60064,
USA) at 0.15mcg∗kg−1∗min−1 administered via the 20g IV
catheter. It is important to note that throughout the entire
procedure the only medication administered through the
20g IV catheter was the Remifentanil infusion. A neurology
team was present to monitor brainstem auditory evoked
potentials (BAERs) during resection of the neuroma. Van-
comycin 1gm IV, Mannitol 70gm IV, Dexamethasone 10mg
IV, and Furosemide 10mg IV were administered via the 18g
IV over recommended time periods. Approximately 45 min-
utes after surgical incision, the patient’s anesthetic require-
ments began to rise such that within 2 hours of incision, he
required 1MAC of Desﬂurane in addition to Nitrous Oxide
and Remifentanil in order to maintain homeostasis. At ap-
proximately 2.5 hours of operating time, the patient became
increasinglytachycardicandwastreatedwith10mgofMeto-
prolol over the next 10 minutes. Train of four (TOF) was
continuously monitored throughout the case, and the trend
of four (TOF) ratio was noted to be 4/4 at 60 minutes after
the initial, and only, dose of cis-atracurium. The patient was
allowed to resume spontaneous ventilation 3hours after in-
duction at which time the tidal volume was 300–400 mil-
liliter (mL), with a respiratory rate of 18-19 breaths per
minute. Morphine, 3mg, IV was administered via the
18g catheter, while the Remifentanil infusion remained at
0.15mcg∗kg−1∗min−1. Remifentanil was discontinued 12
minutes after administration of Morphine, as the patient was
breathingatarateof14–16breathsperminuteandachieving
tidal volumes of 400–500mL. The total surgical time was a
little over 3hours. Surgery was completed 10 minutes after
discontinuation of Nitrous Oxide, 15 minutes after Desﬂu-
rane, 20 minutes after Remifentanil, and 32 minutes after ad-
ministration of Morphine. When the surgical drapes were
taken down, the 20g IV was noted to be inﬁltrated, and the
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apparent that the Remifentanil had been infusing subcuta-
neously for several hours. The presence of adequate circu-
latory ﬂow to the left arm was conﬁrmed by palpation and
Doppler. The patient maintained adequate ventilation and
hemodynamic stability butdid not exhibit any signs of wake-
fulness. He did not exhibit any response to painful stimuli.
At this time, 0.04mg of Naloxone was administered intra-
venously, and the patient began to follow verbal commands.
After meeting extubation criteria, 45minutes after the end of
surgery, the trachea was extubated. Extubation criteria used
included hemodynamic stability, eye opening, ability to fol-
low commands, strong grip, more than 5-second headlift,
swallowing, and purposeful action. The patient was trans-
ported to the recovery room with monitors and supple-
mental nasal cannula oxygen. After his arrival in the recovery
room, he required a second dose of Naloxone, as his level
of consciousness began to decrease. After this time, he did
not exhibit any further signs of sedation. Of note, he did not
complain of pain at the surgical site for several hours after
being received in the recovery room. The total intraoperative
ﬂuids were 1000mL NS, 150mL estimated blood loss (EBL),
and 2100mL urine output (UOP). Normothermia to 37deg-
reesCelsiuswasmaintainedthroughoutthecasewiththeuse
of warming blankets and ﬂuid warmers. The subcutaneous
inﬁltration in the hand resulted in mild blistering but was
treated with warm compresses and resolved over the next
3 days without sequelae. The patient was discharged home
and had uneventful postoperative visits with the surgical
team.
2. Discussion
Delayed awakening is a source of concern in the postopera-
t i v en e u r o s u r g i c a ls e t t i n g .T h i sc a s ep r o v i d e sa ne x a m p l eo f
a neurosurgical patient with delayed emergence after a rela-
tively short general anesthetic. The diﬀerential for this phe-
nomenon is broad, but for the purposes of this discussion,
it includes iatrogenic neurosurgical intracranial pathology,
metabolic derangements, and pharmacologic causes includ-
ing residual benzodiazepine, muscle relaxant, inhalational
agent, and opioid eﬀects [1, 2].
Although diﬃcult to assess without imaging studies or
other cortical function tests done immediately after resec-
tion, the possibility of intracranial pathology remains high
on the diﬀerential. In this particular case, the operative time
was short, and the surgery was uneventful. In addition, there
was minimal blood loss, and brainstem auditory evoked
potentials were appropriately monitored by neurologists
throughout the neuroma resection as it surrounded the left
eighth cranial nerve [3–5]. Desﬂurane, a well-known inhi-
b i t o ro fB A E R s ,w a sk e p tu n d e ro n eM A Ct oa l l o wf o ri n t r a -
operative monitoring and was only increased upon comple-
tion of the actual nerve resection [6]. Follow-up imaging
studies did not reveal any evidence of thrombotic, hemor-
rhagic,orotherintracranialpathology.Inaddition,theuseof
beta blockade has been shown to blunt postoperative hyper-
emia and its deleterious eﬀect following intracranial surgery
[7]. Once fully awake the patient did not exhibit any focal
neurological ﬁndings.
Metabolic derangements can also play a role in delayed
awakening. However, the patient did not have a history of
an endocrine disorder such as diabetes mellitus or hypothy-
roidism,nordidhehaverenalorliverdisease.Despitetheuse
of Mannitol and Furosemide, no postoperative electrolyte
abnormalities were noted in the recovery room.
Pharmacologiccausesofdelayedawakeningfromgeneral
anesthesia are numerous. In this case, all anesthetic agents
used for induction and maintenance were chosen for their
rapid metabolism and short half-life. A relatively healthy 60-
year-old male who received Midazolam, Thiopental, Des-
ﬂurane, Nitrous Oxide, and Remifentanil during his oper-
ation should not have delayed awakening. At the conclu-
sion of surgery, Desﬂurane and Nitrous Oxide levels were
undetectable by end-tidal spectrometry. A 2mg dose of
Midazolam is also unlikely to explain this patient’s periop-
erative course. Morphine administered toward the end of the
procedure was titrated to the patient’s respiratory parame-
ters, and it would seem implausible that a 3mg dose could
cause such an extensive delay. Residual muscle relaxation is
also an unlikely culprit in this case as the patient was able to
maintain adequate spontaneous ventilation prior to the end
of surgery and throughout his immediate postoperative
course.
In light of the improbability of other causes for delayed
awakening, we suggest that it was the accidental subcuta-
neous Remifentanil depot that served as the cause of delayed
emergence in this case. Remifentanil was chosen as the anal-
gesic component of our anesthetic because its use has been
shown to decrease MAC requirements of inhalational agents
while allowing for rapid recovery and cardiovascular and
neurological stability [8–12].
Remifentanil is a congener of the fentanyl family of opi-
oids that was approved for use as a supplement to general
anesthesia by the US Food and Drug Administration in 1996
[13]. It has since become widely used in pediatric, oph-
thalmic, head and neck, and neuroanesthesia [14].
Remifentanil, the hydrochloride salt of 3-[4-methoxy-
carbonyl-4-[(1-oxopropyl)phenylamino]-1-piperidine] pro-
panoic acid methyl ester, is commercially available in a
powder form and must be reconstituted into a solution for
administration [15]. Its metabolism is rapid and clinical use
depends on infusion-based dosing. Any interruption of the
infusion such as an accidental disconnection, pump malfun-
ction, empty drug reservoir, or as in this case inﬁltration of
the IV, leads to a rapid decrease in the anesthetic and anal-
gesic eﬀects requiring further escalation in other anesthetic
agents [16].
The pharmacokinetics of remifentanil have been de-
scribedinnumerousstudiesandhavebeenshowntobemore
closely related to lean body mass than to total body weight
[17]. Several studies have investigated the pharmacodynam-
ics of Remifentanil and found it to be 20–40 times more
potent than Alfentanil and nearly equipotent with Fentanyl
[18, 19]. Remifentanil is rapidly metabolized by nonspeciﬁc
tissueesterasesinbloodandothertissuesincludingthebrain,
liver, placenta, and GI tract [20–22]. However, we found no
study investigating the existence of enzymatic degradation
of Remifentanil in subcutaneous tissues. Also important toCase Reports in Anesthesiology 3
note is that Remifentanil is not a substrate for pseudo-
cholinesterase and, therefore, is not inﬂuenced by pseudo-
cholinesterase deﬁciency [23]. Furthermore, renal and hep-
atic function has been shown not to inﬂuence duration of
its clinical action [24, 25]. However, hypothermia has been
shown to decrease enzymatic function of plasma esterases by
about 20% potentially leading to accumulation of Remifen-
tanil [26].
In the case presented, there were no surgical complica-
tions, blood loss and ﬂuid administration were not excessive,
hepatic and renal functions were not compromised, hypo-
and hypertensions were carefully avoided, and normother-
mia was maintained throughout. The unanticipated need for
increasingintraoperativeanestheticswasmetwithincreasing
doses of Desﬂurane, Metoprolol, and Morphine. The sub-
cutaneous Remifentanil, serving as a depot, caused delayed
awakening and arguably provided postoperative analgesia.
This patient appropriately regained consciousness following
administration of opioid antagonists and did not require any
further pain relief in the immediate postoperative period.
Subcutaneous administration of anesthetic agents has
beenthesubjectofmultipleinvestigations[27,28].However,
we were only able to ﬁnd one other mention of subcutaneous
Remifentanil administration in the literature [29]. Curiously
enough, there are several studies looking at the behavior of
subcutaneously administered Morphine and its metabolites
[27, 28, 30]. One of the more interesting ﬁndings of these
studies is that the metabolism and clinical actions of subcu-
taneously administered opioids are extremely unpredictable
and are associated with a tremendous amount of interuser
variability [27, 30]. Subcutaneously administered insulin
has been shown to act as a slow and steady infusion with
speedofabsorptionaﬀectedbysubcutaneousbloodﬂowand
location of the depot on the patient [31]. Unfortunately,
in reviewing the published kinetics models of Remifentanil,
we were unable to ﬁnd any references to its behavior when
administered subcutaneously [14, 16–21, 32–34]. This raises
the possibility that a drug such as Remifentanil, with an ex-
tremelyfavorablemetabolicproﬁlewhenadministeredintra-
venously, does not behave in the same way when adminis-
tered subcutaneously and may have prolonged opioid eﬀects.
Therefore, caution should be exercised when Remifentanil is
administered as an infusion during operations where the IV
site is not clearly visible.
We have described a case of an inﬁltrated IV leading to
a subcutaneous depot of Remifentanil and prolonging emer-
gence after a relatively quick and otherwise uneventful neu-
rosurgical procedure. Unfortunately, we did not have the ca-
pability to immediately obtain quantitative Remifentanil or
its by-product levels in our laboratory. We also did not yet
have the opportunity to investigate the existence of subcu-
taneous enzymatic degradation of Remifentanil and its po-
tential clinical uses as a subcutaneous depot similar to that of
other narcotics.
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